Clinical trials: CIN3
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancer, Precancerous/Nonmalignant Condition
UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia
RATIONALE: Tretinoin may help cervical neoplasia cells develop into normal cervical cells. It is not yet known whether tretinoin is more effective than a placebo in preventing cervical cancer in patients with cervical neoplasia.
- Trial name
- IRB 1996-0189 (NCT00003598)
- Testing
- tretinoin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cervical Cancer, Precancerous Condition
Study of Pap Smears From Patients Enrolled on Clinical Trial GOG-171
RATIONALE: Studying Pap smears in the laboratory from women with atypical glandular cells of unspecified significance may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898144
- Testing
- Papanicolaou test, laboratory biomarker analysis
- Volunteers
- 55 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer
A Prospective Study Examining the Barriers to Care for Harris County Cervical Cancer Patients
The goal of this behavioral research study is to look at the reasons that may prevent women from getting early treatment for their cervical cancer.
- Trial name
- NCT00519272
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Human Papillomavirus, CIN 2
Natural History of HPV From Infection to Neoplasia in Adolescents and Young Women
The natural history of human papillomavirus (HPV) is most likely influenced by both innate and adaptive mucosal immunity. More specifically, we hypothesize that Toll like receptors (TLR) play an important role in cervical innate…
- Conditions
- Human Papillomavirus, CIN 2, CIN 3
- Trial name
- NCT01366742
- Where
- 2 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Cervical Cancer, Precancerous Condition
Diindolylmethane in Treating Patients With Abnormal Cervical Cells
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of diindolylmethane, a substance found in cruciferous vegetables, may keep cervical intraepithelial neoplasia or cervical cancer from…
- Trial name
- NCT00462813
- Testing
- oral microencapsulated diindolylmethane, polymerase chain reaction, cervical Papanicolaou test
- Where
- 2 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Barts and the London School of Medicine and Dentistry
HPV Infections, Cervical Cancer
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese females aged 9 to 45 years
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT04895020
- Testing
- 9-valent HPV vaccine
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HPV Infections, Cervical Cancer Stage IIa
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05027776
- Testing
- 2-doses Group among 9-14 years, 3-doses Group among 9-19 years, 3-doses Group among 20-26 years
- Where
- China
- Volunteers
- 1,348 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
High-grade squamous intraepithelial lesions (HSIL), encompassing cervical intraepithelial neoplasia grade 2 (CIN2) with p16 positivity and grade 3 (CIN3), are precancerous conditions that require effective intervention.
- Trial name
- Aurora (NCT07669363)
- Testing
- Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), HAL 5% with illumination
- Where
- 28 sites in China
- Volunteers
- 230 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia Grade 3, Human Papilloma Virus Infection
- Trial name
- NCT00054041
- Testing
- HspE7, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.